Local tissue vasodilation (None)

Local tissue vasodilation refers not to a discrete molecular target, but rather to the physiological process by which small arteries and arterioles within a specific region widen in response to increased metabolic demand or decreased oxygen/nutrient supply. This process is mediated by the relaxation of vascular smooth muscle cells, typically triggered by locally released metabolites such as adenosine, carbon dioxide, hydrogen ions (lowered pH), potassium ions, prostaglandins, nitric oxide from endothelial cells—and sometimes by myogenic responses due to changes in vessel wall stretch. The primary function is to increase blood flow specifically where it is needed, ensuring adequate delivery of oxygen and nutrients while removing waste products. This phenomenon underlies important physiological responses such as active hyperemia during exercise or reactive hyperemia after temporary ischemia. While many drugs exploit these pathways therapeutically—by mimicking endogenous mediators—the term "local tissue vasodilation" does not refer to any one protein/receptor/enzyme/transporter that could be considered a canonical drug target. Note on correctness: "Local tissue vasodilation" describes a physiological outcome rather than an individual molecular entity suitable for structured drug-target databases. It should not be listed as a canonical therapeutic target like receptors or enzymes would be.

Other names

Local vasodilationTissue vasodilationLocal blood flow regulation (sometimes used interchangeably, but not strictly synonymous)

Not applicable for "local tissue vasodilation" itself. Mechanisms for drugs that cause this effect include: - Increase in cGMP via nitric oxide pathway (e.g., nitrovasodilators) - Increase in cAMP via prostacyclin pathway - Blockade of calcium channels leading to smooth muscle relaxation - Direct activation of potassium channels causing hyperpolarization and relaxation